Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55455, United States.
Chem Res Toxicol. 2023 Jul 17;36(7):1071-1080. doi: 10.1021/acs.chemrestox.3c00047. Epub 2023 Jun 22.
Overdose of acetaminophen, a widely used antipyretic and analgesic drug, is one of the leading causes of drug-induced acute liver injury in the United States and worldwide. Phase-I metabolism of acetaminophen generates the toxic -acetyl--benzoquinone imine (NAPQI) intermediate. Reactions of NAPQI with a wide range of biomolecules cause increased oxidative stress, endoplasmic reticulum (ER) stress, inflammation, and mitochondrial dysfunction, some of the cellular events contributing toward liver toxicity. Previously, we evaluated the potential of an FDA-approved, ER stress-modulating antihypertensive drug, Wytensin (-guanabenz, -GA), as an antidote for acetaminophen hepatotoxicity. -GA prevented elevation of the liver enzyme alanine aminotransferase (ALT), even when administered up to 6 h after acetaminophen overdose, and exhibited synergistic analgesic interactions. However, the commercially available guanabenz exists solely as a trans-isomer and suffers from sedative side effects resulting from the inhibition of central α-adrenergic receptors in locus coeruleus. Here, we studied the utility of the relatively unexplored cis-isomer of guanabenz as a treatment option for acetaminophen-induced liver toxicity. ()-Guanabenz acetate (GA) lacks interaction with α-adrenoreceptors and is thus devoid of sedative, blood-pressure-lowering side effects of -GA. Treatment of mice with GA (10 mg/kg) before acetaminophen overdose and up to 6 h post APAP administration prevented liver injury and suppressed the elevation of serum ALT levels. Mechanistically, hepatoprotective effects of both isomers are similar and partly attributed to attenuation of the ER stress and oxidative stress in the liver. The results of this study suggest that -GA may be a safer, effective antidote for the clinical management of acute liver injury resulting from acetaminophen overdose. It also raises a tantalizing possibility of a prophylactic combination of the geometric isomer of the approved drug guanabenz with acetaminophen in a clinical setting.
对乙酰氨基酚过量是美国和全球范围内导致药物性急性肝损伤的主要原因之一,对乙酰氨基酚是一种广泛使用的解热镇痛药。对乙酰氨基酚的 I 相代谢生成有毒的 -乙酰- -苯醌亚胺(NAPQI)中间产物。NAPQI 与多种生物分子的反应导致氧化应激、内质网(ER)应激、炎症和线粒体功能障碍增加,这些细胞事件是导致肝毒性的部分原因。此前,我们评估了一种已获美国食品和药物管理局(FDA)批准的、调节内质网应激的抗高血压药物 Wytensin(胍那苄,-GA)作为对乙酰氨基酚肝毒性解毒剂的潜力。即使在对乙酰氨基酚过量后 6 小时内给予 -GA,也能防止肝酶丙氨酸氨基转移酶(ALT)升高,并表现出协同的镇痛相互作用。然而,市售的胍那苄仅以反式异构体存在,由于抑制蓝斑核中的中枢α-肾上腺素能受体而产生镇静副作用。在这里,我们研究了胍那苄的顺式异构体作为治疗对乙酰氨基酚诱导的肝毒性的选择的效用。()-胍那苄乙酸盐(GA)与α-肾上腺素能受体无相互作用,因此没有镇静、降血压的副作用。在对乙酰氨基酚过量前和 APAP 给药后 6 小时内用 GA(10mg/kg)治疗小鼠可预防肝损伤并抑制血清 ALT 水平升高。两种异构体的肝保护作用机制相似,部分归因于减轻肝脏内质网应激和氧化应激。这项研究的结果表明,-GA 可能是一种更安全、有效的解毒剂,可用于治疗对乙酰氨基酚过量引起的急性肝损伤。它还提出了一个诱人的可能性,即在临床环境中,将批准药物胍那苄的几何异构体与对乙酰氨基酚预防性组合。